title: What is stopping the NHS from using bevacizumab for macular degeneration and other retinal disorders?
authors.affiliation: Clinical and Experimental Sciences, Faculty of Medicine, University Hospital Southampton, Southampton SO16 6YD, UK A.J.Lotery@soton.ac.uk.
authors.forename: Andrew
authors.initials: A
authors.lastname: Lotery
authors.affiliation: Royal College of Ophthalmologists, London NW1 4QW, UK.
authors.forename: Carrie
authors.initials: C
authors.lastname: MacEwen
mesh_terms: D020533:Angiogenesis Inhibitors / Q000191:economics / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000191:economics / Q000627:therapeutic use*; D000068258:Bevacizumab; D017277:Drug Approval / Q000191:economics; D006801:Humans; D008268:Macular Degeneration / Q000188:drug therapy* / Q000191:economics; D000069579:Ranibizumab; D012164:Retinal Diseases / Q000188:drug therapy*; D013222:State Medicine / Q000191:economics; D006113:United Kingdom
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D000069579:Ranibizumab